News and Trends 25 Jul 2022 Macao university research finds mRNA vaccine booster offers more protection against Omicron variants A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Replay launches with $55M to reprogram biology by writing and delivering big DNA Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has launched with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Replay, which is based in San Diego, Cal., and London, U.K., […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 25 Jul 2022 How to improve patient recruitment in your precision medicine research Precision medicine research relies on genetic testing at scale, but has long suffered recruitment and retention headaches. The answer, says Patrick Short, CEO of Sano Genetics, is to start early and engage participants deeply. I witnessed first-hand the power of national scale genomics research through my PhD work analyzing genome sequence data from more than […] July 25, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 22 Jul 2022 The coming of age story of RNAi technology The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […] July 22, 2022 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Australia looks to biotech alliance The Australian government’s Defence department has announced the launch of the Safeguarding Australia through Biotechnology Response and Engagement alliance (SABRE) at the inaugural Australian Defence Science Technology and Research Summit (ADSTAR) The department said SABRE offers opportunities by bringing together different perspectives of biotech from Australia’s universities, research institutes and small medium enterprises (SME) and […] July 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Astellas to create new biotech campus in South San Francisco Astellas Pharma Inc. has unveiled plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-square-foot building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the San Francisco area. The new innovation […] July 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Stroke drug given priority medicine status by European Medicines Agency A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […] July 22, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Consortium awarded €4M towards platform for personalized cell therapies A company developing precision T cell therapies that treat solid tumors announced yesterday (July 21) it is leading a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe. The new consortium is being led by Achilles Therapeutics plc and includes CGT Catapult, Leibniz University Hannover (Hannover) as project coordinator, and […] July 22, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email